在FDA对支持人工智能的医疗器械的营销授权中区分严格和透明度
Abdul Rahman Diab1, William Lotter1,2,3
1Department of Data Science, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215.
Radiology. Artificial intelligence
|September 24, 2025
概括
人工智能 (AI) 医疗设备需要严格的验证和透明的报告,以确保安全的临床使用. 这项研究澄清了AI设备验证标准,并提出了改善信任和实用性的建议.
科学领域:
- 医疗器械监管法规 医疗器械监管法规
- 医疗保健中的人工智能
- 放射学人工智能的人工智能
背景情况:
- 越来越多的人工智能医疗设备的使用为患者提供了改善的结果.
- 人工智能设备在获得FDA营销许可之前的验证程度存在担忧.
- 公开的FDA摘要缺乏全面的验证数据.
研究的目的:
- 澄清美国食品和药物管理局 (FDA) 对人工智能设备的监管概念.
- 提供有关放射学AI当前性能验证标准的见解.
- 区分验证严谨性和验证透明度.
主要方法:
- 对FDA指导方针和提交组件的分析.
- 对人工智能医疗设备的FDA公开摘要的审查.
- 将放射学AI设备类型映射到临床研究设计.
主要成果:
- 绩效数据量与提交透明度之间存在一个反向关系.
- 目前对人工智能设备的验证标准因类型和预期用途而异.
- 放射学AI设备验证往往缺乏全面的公共报告.
结论:
- 为平衡的验证方法提出了可行的建议.
- 倡导人工智能设备评估和报告的通用标准.
- 确保严格的评估和透明的报告促进了公众的信任和临床实用性.
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
235
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
235
Clinically Relevant Drug Product Specifications: Methods of Establishment
205
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
205
FDA Approved Drugs: Changes to Approved Drugs
244
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
244
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Bioequivalence studies: Biowaivers
227
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
227
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K


